Rheumatoid Factor and Anti Citrulinated Peptide. Relation with Remission and Progression in Rheumatoid Arthritis with Biologic Agent Therapy, during a One-Year Follow-Up
作者： Asunción Acosta Pereira , Berta Magallares López , Esther Moga Naranjo , Arturo Rodríguez de la Serna
关键词:
摘要: The aim of this study is to assess the variations RF and ACCP in RA patients treated with biologics actual clinical practice (real) conditions for a one-year follow-up from first biologic medication. evaluated diagnosis RA, according American College Rheumatology (ACR) 1987 were selected outpatient consult “Hospital de Sant Pau” during one month (November 2012). We collected analyzed data 41 positivity and/or ACCP. Of had given FR at 3, 6 12 months respectively 18 10 patients. In 22 DAS 28 respectively. mean age sample 55 years (range 29-79), disease progression 9 (4 32 years). 70% are women. 33 (80.5%) initiated treatment anti-TNF 8 (19.5%) other no mechanism action. There was statistically significant (p = 0.001, ANOVA) decrease (average 1.6 points) 3 maintained m differences their evolution by separating drugs vs. biological agents (different mechanisms action 0.285). So we have not detected correlation between or along treatment. our experience did find ACCP, thus do appear predict response
sci-hub.st 参考文章(25)
Akihito Ishigami, Naoki Maruyama, Importance of research on peptidylarginine deiminase and citrullinated proteins in age‐related disease Geriatrics & Gerontology International. ,vol. 10, ,(2010) , 10.1111/J.1447-0594.2010.00593.X
William J. Koopman, Arthritis and allied conditions: A textbook of rheumatology ,(1989)
William N. Kelley, Textbook of Rheumatology ,(1985)
F. BOBBIO-PALLAVICINI, R. CAPORALI, C. ALPINI, R. MORATTI, C. MONTECUCCO, Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti‐TNF‐α Treated Patients Annals of the New York Academy of Sciences. ,vol. 1109, pp. 287- 295 ,(2007) , 10.1196/ANNALS.1398.034
K. N. Verpoort, C. M. Jol-van der Zijde, E. A. M. Papendrecht-van der Voort, A. Ioan-Facsinay, J. W. Drijfhout, M. J. D. van Tol, F. C. Breedveld, T. W. J. Huizinga, R. E. M. Toes, Isotype distribution of ANTI–CYCLIC citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response Arthritis & Rheumatism. ,vol. 54, pp. 3799- 3808 ,(2006) , 10.1002/ART.22279
the Late BERNARD I. COMROE, JOSEPH L. HOLLANDER, ARTHRITIS AND ALLIED CONDITIONS The American Journal of the Medical Sciences. ,vol. 218, pp. 151- ,(1949) , 10.1097/00000441-194911000-00026
M Sebbag, M Simon, C Vincent, C Masson-Bessière, E Girbal, J J Durieux, G Serre, The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. Journal of Clinical Investigation. ,vol. 95, pp. 2672- 2679 ,(1995) , 10.1172/JCI117969
Hiba Mahdi, Benjamin A Fisher, Henrik Källberg, Darren Plant, Vivianne Malmström, Johan Rönnelid, Peter Charles, Bo Ding, Lars Alfredsson, Leonid Padyukov, Deborah P M Symmons, Patrick J Venables, Lars Klareskog, Karin Lundberg, Specific interaction between genotype, smoking and autoimmunity to citrullinated |[alpha]|-enolase in the etiology of rheumatoid arthritis Nature Genetics. ,vol. 41, pp. 1319- 1324 ,(2009) , 10.1038/NG.480
Gerard A. Schellekens, Hendrik Visser, Ben A. W. De Jong, Frank H. J. Van Den Hoogen, Johanna M. W. Hazes, Ferdinand C. Breedveld, Walther J. Van Venrooij, The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis & Rheumatism. ,vol. 43, pp. 155- 163 ,(2000) , 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3
Solbritt Rantapää-Dahlqvist, Ben A. W. de Jong, Ewa Berglin, Göran Hallmans, Göran Wadell, Hans Stenlund, Ulf Sundin, Walther J. van Venrooij, Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis & Rheumatism. ,vol. 48, pp. 2741- 2749 ,(2003) , 10.1002/ART.11223